相关临床试验
57
8 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1818
进行中（未招募）
3
5.3%
已完成
35
61.4%
尚未招募
5
8.8%
招募中
5
8.8%
终止
2
3.5%
Unknown
5
8.8%
撤回
2
3.5%
暂无批准数据
- A new MRI study published in Nature/NPJ Imaging demonstrates how BioVaxys' MVP-S vaccine combined with checkpoint inhibitors and cyclophosphamide significantly reduces tumor volume in ovarian cancer models. - The preclinical research led by Dalhousie University researchers used magnetic resonance imaging to track immune cell infiltration, showing increased myeloid and CD8+ T cells in tumors treated with the combination therapy. - The findings validate the immune response mechanism of MVP-S, which targets survivin-expressing tumor cells and is currently in phase II development for platinum-resistant ovarian cancer. - The study supports the ongoing PESCO trial combining MVP-S with pembrolizumab and cyclophosphamide in recurrent epithelial ovarian cancer patients, with results to be presented at ASCO 2026.
- A small-scale gene therapy study for Fabry disease enabled three of five male patients to discontinue costly enzyme-replacement therapy, generating $3.7 million in savings against $4 million research costs. - The experimental treatment uses bone marrow stem cells to deliver replacement copies of faulty genes, with patients maintaining elevated enzyme production five years post-treatment. - Researchers plan to expand the study to 25-30 patients including women over two to three years, as the current therapy requires bi-weekly treatments costing $300,000 annually per patient. - The gene therapy demonstrated a favorable safety profile with only two minor side effects related to preparatory chemotherapy rather than the gene therapy itself.
- BioVaxys Technology and Sona Nanotech have formed a research collaboration to develop innovative cancer therapeutics by combining BioVaxys' DPX immune educating platform with Sona's targeted hyperthermia therapy using gold nanorods. - The joint research will evaluate the immune-stimulatory properties of DPX administered with photothermal cancer therapy, as well as explore DPX as a carrier for neoantigens expressed on tumor cell surfaces following immunotherapy. - Studies will be conducted at Dalhousie University under Sona's CMO Dr. Carman Giacomantonio, with both companies sharing ownership of any novel therapeutic candidates developed through the program.
- A new study suggests ablation should be considered as a first-line treatment for ventricular tachycardia (VT) in heart attack survivors, rather than a secondary option after medication failure. - Ablation was found to reduce the risk of death or VT episodes requiring defibrillator shocks by 25% compared to anti-arrhythmic medications. - The minimally invasive procedure targets and destroys abnormal heart tissue causing VT, offering a more direct approach than systemic drug therapies. - Researchers emphasize the need for further studies to identify which patients would benefit most from ablation versus medication for post-heart attack VT.
